Switch theme
Sign up to access all valuation multiples
Egetis Therapeutics AB is an integrated pharmaceutical drug development company, focusing on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment.
2007
11
LTM Revenue $10.5M
LTM EBITDA -$28.6M
$108M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Egetis Therapeutics has a last 12-month revenue (LTM) of $10.5M and a last 12-month EBITDA of -$28.6M.
In the most recent fiscal year, Egetis Therapeutics achieved revenue of $4.8M and an EBITDA of -$33.2M.
Egetis Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Egetis Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $10.5M | XXX | $4.8M | XXX | XXX | XXX |
| Gross Profit | $8.5M | XXX | $3.6M | XXX | XXX | XXX |
| Gross Margin | 81% | XXX | 75% | XXX | XXX | XXX |
| EBITDA | -$28.6M | XXX | -$33.2M | XXX | XXX | XXX |
| EBITDA Margin | -273% | XXX | -699% | XXX | XXX | XXX |
| EBIT | -$28.6M | XXX | -$33.2M | XXX | XXX | XXX |
| EBIT Margin | -273% | XXX | -698% | XXX | XXX | XXX |
| Net Profit | -$30.0M | XXX | -$35.4M | XXX | XXX | XXX |
| Net Margin | -286% | XXX | -745% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Egetis Therapeutics's stock price is SEK 3 (or $0).
Egetis Therapeutics has current market cap of SEK 1.2B (or $126M), and EV of SEK 1.0B (or $108M).
See Egetis Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $108M | $126M | XXX | XXX | XXX | XXX | $-0.08 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Egetis Therapeutics has market cap of $126M and EV of $108M.
Egetis Therapeutics's trades at 22.7x EV/Revenue multiple, and -3.3x EV/EBITDA.
Equity research analysts estimate Egetis Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Egetis Therapeutics has a P/E ratio of -4.2x.
See valuation multiples for Egetis Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $126M | XXX | $126M | XXX | XXX | XXX |
| EV (current) | $108M | XXX | $108M | XXX | XXX | XXX |
| EV/Revenue | 10.3x | XXX | 22.7x | XXX | XXX | XXX |
| EV/EBITDA | -3.8x | XXX | -3.3x | XXX | XXX | XXX |
| EV/EBIT | -3.8x | XXX | -3.3x | XXX | XXX | XXX |
| EV/Gross Profit | 12.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | -4.2x | XXX | -3.6x | XXX | XXX | XXX |
| EV/FCF | -4.3x | XXX | -4.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialEgetis Therapeutics's last 12 month revenue growth is 270%
Egetis Therapeutics's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $3.3M for the same period.
Egetis Therapeutics's rule of 40 is -284% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Egetis Therapeutics's rule of X is 402% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Egetis Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 270% | XXX | 277% | XXX | XXX | XXX |
| EBITDA Margin | -273% | XXX | -699% | XXX | XXX | XXX |
| EBITDA Growth | -87% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -284% | XXX | -428% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 402% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $3.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 238% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 317% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 773% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Egetis Therapeutics acquired XXX companies to date.
Last acquisition by Egetis Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Egetis Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Egetis Therapeutics founded? | Egetis Therapeutics was founded in 2007. |
| Where is Egetis Therapeutics headquartered? | Egetis Therapeutics is headquartered in Sweden. |
| How many employees does Egetis Therapeutics have? | As of today, Egetis Therapeutics has 11 employees. |
| Who is the CEO of Egetis Therapeutics? | Egetis Therapeutics's CEO is Mr. Nicklas Westerholm. |
| Is Egetis Therapeutics publicy listed? | Yes, Egetis Therapeutics is a public company listed on STO. |
| What is the stock symbol of Egetis Therapeutics? | Egetis Therapeutics trades under EGTX ticker. |
| When did Egetis Therapeutics go public? | Egetis Therapeutics went public in 2011. |
| Who are competitors of Egetis Therapeutics? | Similar companies to Egetis Therapeutics include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Egetis Therapeutics? | Egetis Therapeutics's current market cap is $126M |
| What is the current revenue of Egetis Therapeutics? | Egetis Therapeutics's last 12 months revenue is $10.5M. |
| What is the current revenue growth of Egetis Therapeutics? | Egetis Therapeutics revenue growth (NTM/LTM) is 270%. |
| What is the current EV/Revenue multiple of Egetis Therapeutics? | Current revenue multiple of Egetis Therapeutics is 10.3x. |
| Is Egetis Therapeutics profitable? | Yes, Egetis Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Egetis Therapeutics? | Egetis Therapeutics's last 12 months EBITDA is -$28.6M. |
| What is Egetis Therapeutics's EBITDA margin? | Egetis Therapeutics's last 12 months EBITDA margin is -273%. |
| What is the current EV/EBITDA multiple of Egetis Therapeutics? | Current EBITDA multiple of Egetis Therapeutics is -3.8x. |
| What is the current FCF of Egetis Therapeutics? | Egetis Therapeutics's last 12 months FCF is -$24.9M. |
| What is Egetis Therapeutics's FCF margin? | Egetis Therapeutics's last 12 months FCF margin is -238%. |
| What is the current EV/FCF multiple of Egetis Therapeutics? | Current FCF multiple of Egetis Therapeutics is -4.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
